DE60235610D1 - Verwendung einer Soja Zelllinie mit hohem Isoflavon Gehalt - Google Patents

Verwendung einer Soja Zelllinie mit hohem Isoflavon Gehalt

Info

Publication number
DE60235610D1
DE60235610D1 DE60235610T DE60235610T DE60235610D1 DE 60235610 D1 DE60235610 D1 DE 60235610D1 DE 60235610 T DE60235610 T DE 60235610T DE 60235610 T DE60235610 T DE 60235610T DE 60235610 D1 DE60235610 D1 DE 60235610D1
Authority
DE
Germany
Prior art keywords
cell line
isoflavone content
high isoflavone
soya
soy cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60235610T
Other languages
English (en)
Inventor
Ermanno Federici
Andre Touche
Didier Courtois
Vincent Petiard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Application granted granted Critical
Publication of DE60235610D1 publication Critical patent/DE60235610D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60235610T 2002-04-30 2002-04-30 Verwendung einer Soja Zelllinie mit hohem Isoflavon Gehalt Expired - Lifetime DE60235610D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02009810A EP1359215B1 (de) 2002-04-30 2002-04-30 Verwendung einer Soja Zelllinie mit hohem Isoflavon Gehalt

Publications (1)

Publication Number Publication Date
DE60235610D1 true DE60235610D1 (de) 2010-04-22

Family

ID=28799673

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60235610T Expired - Lifetime DE60235610D1 (de) 2002-04-30 2002-04-30 Verwendung einer Soja Zelllinie mit hohem Isoflavon Gehalt

Country Status (9)

Country Link
US (1) US7354765B2 (de)
EP (2) EP1359215B1 (de)
JP (1) JP4343828B2 (de)
AT (1) ATE460474T1 (de)
AU (1) AU2003227617B2 (de)
CA (1) CA2484258A1 (de)
DE (1) DE60235610D1 (de)
NO (1) NO20045212L (de)
WO (1) WO2003093456A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3960802B2 (ja) * 2000-03-02 2007-08-15 マイクロチップス・インコーポレーテッド 化学物質およびデバイスを格納し、選択的に露出させるための微細加工されたデバイス
WO2005074710A1 (en) * 2004-02-06 2005-08-18 Konkuk University Industrial Coorperation Corp Sprouted bean containing high concentration of isoflavone and the preparing method thereof
WO2014052494A1 (en) * 2012-09-26 2014-04-03 Dianaplantsciences, S.A.S. Novel food compositions of whole plant cells
CN106028795B (zh) 2013-12-13 2020-03-03 庆尚大学校产学协力团 具有高含量异黄酮衍生物的豆叶或豆茎及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4992375A (en) * 1983-11-25 1991-02-12 Monsanto Company Method of regenerating soybeans from cultured soybean cotyledonary nodes
JPH05176756A (ja) 1991-12-27 1993-07-20 Idemitsu Kosan Co Ltd Ｖａ菌根菌製剤の保存方法
US5702752A (en) 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
US5821361A (en) 1996-06-11 1998-10-13 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses

Also Published As

Publication number Publication date
ATE460474T1 (de) 2010-03-15
JP4343828B2 (ja) 2009-10-14
EP1359215A1 (de) 2003-11-05
AU2003227617B2 (en) 2008-05-15
AU2003227617A1 (en) 2003-11-17
CA2484258A1 (en) 2003-11-13
NO20045212L (no) 2005-01-28
EP1501919A1 (de) 2005-02-02
US7354765B2 (en) 2008-04-08
JP2005523721A (ja) 2005-08-11
EP1359215B1 (de) 2010-03-10
WO2003093456A1 (en) 2003-11-13
US20050050589A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
ATE334220T1 (de) Verfahren zur herstellung von l-aminosäuren unter verwendung von stämmen der familie enterobacteriaceae
ATE553210T1 (de) Verfahren zur herstellung von l-threonin unter verwendung eines mikroorganismus mit inaktivierten galr gen.
BRPI0613543B8 (pt) Método para produção de 1,3-propanodiol usando glicerol bruto, um subproduto da produção de biodiesel
ATE282710T1 (de) Verfahren zur fermentativen herstellung von cytostatika und deren kristallformen
ATE425136T1 (de) Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
ATE486857T1 (de) Verfahren zur herstellung von telmisartan
ATE356084T1 (de) Verfahren zur herstellung eines silicoaluminophosphat-molekularsiebs
GB0308407D0 (en) Method of obtaining 68 GA
DE50111753D1 (de) Epothilon-synthesebausteine i: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie deren verwendung zur herstellung von epothilonen und epothilonderivaten
DE502006000347D1 (de) Oberflächenbelegte perlglanzpigmente, verfahren zu deren herstellung und deren verwendung
DE60306667D1 (de) Cefdinir salze als zwischenprodukte
DE60235610D1 (de) Verwendung einer Soja Zelllinie mit hohem Isoflavon Gehalt
ATE452180T1 (de) Blakeslea trispora zur herstellung von lycopin in hoher ausbeute, in einem geeigneten medium in abwesenheit eines exogenen corotenogenese- hemmstoffes
ATE415404T1 (de) Lösungsmittelfreies verfahren zur herstellung von diketopyrrolopyrrol-derivaten
DE60105314D1 (de) Verfahren zur herstellung von taxanderivaten
AU2001228468A1 (en) Working up a mixture comprising alkene and oxygen
ATE356110T1 (de) Verfahren zur herstellung von kristallinem cholinascorbat
DE60235820D1 (de) Verfahren zur herstellung von azoverbindungen
DE50209497D1 (de) Methode zur herstellung von magnesiumdiborid sowie von magnesiumdiborid-formkörpern aus magnesiumhydrid und elementarem bor mittels puls-plasma-synthese
WO2004024681A3 (fr) NOUVEAUX COMPOSES COMPRENANT UN GROUPEMENT THIOCARBONYLSULFANYLE UTILES POUR LA SYNTHESE DE COMPOSES α-PERFLUOROALKYLAMINES PAR VOIE RADICALAIRE
DE50109832D1 (de) Verfahren zur herstellung von essigsäure
AU2002241277A1 (en) Functional plant, promoter to be used for producing the functional plant and method of using the same
DE60319049D1 (de) Mikroorganismus zur Herstellung von Riboflavin, und seine Verwendung in der Herstellung von Riboflavin
HUP9903899A2 (hu) Eljárás L-aminosavak fermentációs előállítására
DE69915951D1 (de) Verfahren zur Herstellung von Pyrrolidinderivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition